Do GLP-1 pens need to stay refrigerated during travel
A former athlete who had dreamed of a career in professional soccer
A six-figure monthly revenue that grows consistently, month after month
Tirzepatide is a dual agonist targeting both GLP-1 and GIP receptors, improving insulin sensitivity and promoting fullness, leading to superior weight losssome patients lose over 20%, with an average of 15%
Genetic variations, diet, and age also play a role, as can taking certain medications, such as birth control pills
Key Growth Drivers of the GLP-1 Weight Loss Drug Market Three Structural Catalysts Driving GLP-1 Weight Loss Drug Market Expansion Through 2035 Obesity epidemic scale: More than 1.1 billion adults with obesity globally representing a potential pharmacotherapy patient pool approximately 25 times larger than current GLP-1 prescribing volumes, with only 2.3% of eligible U.S